On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development solutions for the five million people with pelvic and bladder pain, announced the the U.S. National Library of Medicine Clinical Trials website has listed Vaneltix’s new round of clinical trials.
Read more: Vaneltix ClinicalTrials.GOV
About Vaneltix
Vaneltix Pharma, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products focused on repurposed products that can be developed through the FDA 505(b)(2) regulatory pathway. Vaneltix’s development programs target significant unmet medical need and major market opportunities in urology and women’s health care. Vaneltix’s lead clinical program is AlenuraTM, a proprietary combination of the approved drugs lidocaine and heparin that is instilled into the bladder, and targets IC/BPS, an unmet medical need which affects at least 6 million 1 men and women in the US. For further information, please visit Vaneltix’s website at http://www.vaneltix.com.
